M6P/IGF2R is mutated in squamous cell carcinoma of the lung

Feng Ming Kong, Mitchell S. Anscher, Mary K. Washington, J. Keith Killian, Randy L. Jirtle

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA. Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus. The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.

Original languageEnglish (US)
Pages (from-to)1572-1578
Number of pages7
JournalOncogene
Volume19
Issue number12
DOIs
StatePublished - Mar 16 2000

Fingerprint

Squamous Cell Carcinoma
Loss of Heterozygosity
Lung
Neoplasms
IGF Type 2 Receptor
3' Untranslated Regions
Biological Availability
Cause of Death
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Peptide Hydrolases
Alleles
Pathology
Polymerase Chain Reaction
Mutation
DNA
Enzymes
Growth
mannose-6-phosphate

Keywords

  • Loss of heterozygosity
  • Lung cancer
  • M6P/IGF2R
  • Mutation
  • Tumor suppressor

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K., & Jirtle, R. L. (2000). M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene, 19(12), 1572-1578. https://doi.org/10.1038/sj.onc.1203437

M6P/IGF2R is mutated in squamous cell carcinoma of the lung. / Kong, Feng Ming; Anscher, Mitchell S.; Washington, Mary K.; Killian, J. Keith; Jirtle, Randy L.

In: Oncogene, Vol. 19, No. 12, 16.03.2000, p. 1572-1578.

Research output: Contribution to journalArticle

Kong, FM, Anscher, MS, Washington, MK, Killian, JK & Jirtle, RL 2000, 'M6P/IGF2R is mutated in squamous cell carcinoma of the lung', Oncogene, vol. 19, no. 12, pp. 1572-1578. https://doi.org/10.1038/sj.onc.1203437
Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene. 2000 Mar 16;19(12):1572-1578. https://doi.org/10.1038/sj.onc.1203437
Kong, Feng Ming ; Anscher, Mitchell S. ; Washington, Mary K. ; Killian, J. Keith ; Jirtle, Randy L. / M6P/IGF2R is mutated in squamous cell carcinoma of the lung. In: Oncogene. 2000 ; Vol. 19, No. 12. pp. 1572-1578.
@article{ea46930b63a641ce8c408dab6221831d,
title = "M6P/IGF2R is mutated in squamous cell carcinoma of the lung",
abstract = "In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA. Nineteen of 22 (86{\%}) patients were informative (heterozygous), and 11/19 (58{\%}) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus. The remaining allele in 6/11 (55{\%}) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.",
keywords = "Loss of heterozygosity, Lung cancer, M6P/IGF2R, Mutation, Tumor suppressor",
author = "Kong, {Feng Ming} and Anscher, {Mitchell S.} and Washington, {Mary K.} and Killian, {J. Keith} and Jirtle, {Randy L.}",
year = "2000",
month = "3",
day = "16",
doi = "10.1038/sj.onc.1203437",
language = "English (US)",
volume = "19",
pages = "1572--1578",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - M6P/IGF2R is mutated in squamous cell carcinoma of the lung

AU - Kong, Feng Ming

AU - Anscher, Mitchell S.

AU - Washington, Mary K.

AU - Killian, J. Keith

AU - Jirtle, Randy L.

PY - 2000/3/16

Y1 - 2000/3/16

N2 - In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA. Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus. The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.

AB - In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA. Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus. The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.

KW - Loss of heterozygosity

KW - Lung cancer

KW - M6P/IGF2R

KW - Mutation

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=0034673761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034673761&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1203437

DO - 10.1038/sj.onc.1203437

M3 - Article

VL - 19

SP - 1572

EP - 1578

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 12

ER -